Aim: To assess the impact that pregestational insulin resistance (PIR) has as a risk factor for preeclampsia (PE). Methods: Nested case-control study that included patients with PIR and a control group that was randomly selected from pregnancies admitted to the Fetal Medicine Unit between January 2005 and May 2011. Clinical and hemodynamic variables were analyzed by a multiple logistic regression analysis. Results: Of the 13,124 patients admitted during the study period, 119 had a diagnosis of PIR (0.9%). Patients with PIR were older and had a higher body mass index (BMI). PIR was also related to a significantly higher frequency of chronic hypertension (CrHT; 10.1 vs. 2.2%, p < 0.05) and hypothyroidism (5.0 vs. 1.6%, p < 0.05) than in the control group. Moreover, women with PIR were more likely to develop PE (8.4 vs. 4.2%, p < 0.05) and gestational diabetes mellitus (9.2 vs. 2.9%) than the control group. Multivariate analysis showed that maternal age, CrHT and altered uterine artery Doppler sonography during the first and second trimesters were good predictors of PE and that PIR was not. Conclusion: Although PIR correlates with PE, conditions related to the latter (CrHT, higher maternal age and increased BMI) may be predominant as risk factors for PE.

Keywords:
Insulin resistance, Preeclampsia, Pregnancy, Doppler sonography, Hypothyroidism
1.
Khong TY, De Wolf F, Robertson WB, Brosens I: Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and by small for gestational age infants. Br J Obstet Gynaecol 1986;93:1049-1059.
2.
Roberts JM, Redman CWG: Pre-eclampsia: more than pregnancy induced hypertension. Lancet 1993;341:1447-1454.
3.
Campbell S, Pearce JM, Hackett G, Cohen-Overbeek T, Hernandez C: Qualitative assessment of uteroplacental blood flow: early screening test for high-risk pregnancies. Obstet Gynecol 1986;68:649-653.
4.
Sibai BM: Prevention of preeclampsia: a big disappointment. Am J Obstet Gynecol 1998;179:1275-1278.
5.
Arngrimsson R, Björnsson S, Geirsson RT, Björnsson H, Walker JJ, Snaedal G: Genetic and familial predisposition to eclampsia and preeclampsia in a defined population. Br J Obstet Gynecol 1990;97:762-769.
6.
Robillard Py, Hulsey TC, Perianin J, Janky E, Miri EH, Papiernik E: Association of pregnancy induced hypertension with duration of sexual cohabitation before conception. Lancet 1994;344:973-975.
7.
Redman CW, Saks, GP, Sargent IL: Preeclampsia and excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999;180:499-506.
8.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides K: Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011;31:66-74.
9.
Timar O, Sestier F, Levy E: Metabolic syndrome X: a review. Can J Cardiol 2000;16:779-789.
10.
Prado J, Ortiz JA, López JL: Insulinoresistencia en la mujer. Rev Chil Obstet Ginec 2000;66:454-458.
11.
Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;16:356-359.
12.
Adams J, Polson DW, Franks S: Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J 1986;293:355-359.
13.
Adam PA, Teramo K, Raiha N, Gitlin D, Schwartz R: Human fetal insulin metabolism early in gestation. Response to acute elevation of the fetal glucose concentration and placental transfer of human insulin-I-131. Diabetes 1969;18:409-416.
14.
Milner RD, Ashworth MA, Barson AJ: Insulin release from human foetal pancreas in response to glucose, leucine and arginine. J Endocrinol 1972;52:497-505.
15.
Gillmer MD, Beard RW, Brooke FM, Oakley NW: Carbohydrate metabolism in pregnancy. I. Diurnal plasma glucose profile in normal and diabetic women. Br Med J 1975;3:399-402.
16.
Ciaraldi TP, Kettel M, El-Roeiy A, et al: Mechanisms of cellular insulin resistance in human pregnancy. Am J Obstet Gynecol 1994;170:635-641.
17.
Valdés ER, Lattes KA, Muñoz HS, Barja PY, Papapietro KV: First-trimester adiponectin and subsequent development of preeclampsia or fetal growth restriction. Gynecol Obstet Invest 2011;72:152-156.
18.
Solomon CG, Seely EW: Hypertension in pregnancy: a manifestation of the insulin resistance syndrome? Hypertension 2001;37:232-239.
19.
Wolf M, Sandler L, Muñoz K, Hsu K, Ecker JL, Thadhani R: First trimester insulin resistance and subsequent preeclampsia: a prospective study. J Clin Endocrinol Metab 2002;87:1563-1568.
20.
Spencer K, Yu CK, Rembouskos G, Binda R, Nicolaides KH: First trimester sex hormone-binding globulin and subsequent preeclampsia or other adverse pregnancy outcomes. Hypertens Pregnancy 2005;24:303-311.
21.
Wolf M, Sandler L, Jimenez-Kimble R, Shah A, Ecker J, Thadhani R: Insulin resistance but not inflammation is associated with gestational hypertension. Hypertension 2002;40:886-891.
22.
Yu CK, Papageorghiou AT, Binda R, Spencer K, Nicolaides KH: Second-trimester sex hormone-binding globulin and subsequent development of pre-eclampsia. J Matern Fetal Neonatal Med 2004;16:158-162.
23.
Hauth J, Clifton R, Roberts J, Myatt L, Spong C, Leveno K, et al: Maternal insulin resistance and preeclampsia. Am J Obstet Gynecol 2011;204:327e1-327e6.
24.
Alvarez JA, Bush NC, Hunter GR, Brock DW, Gower BA: Ethnicity and weight status affect the accuracy of proxy indices of insulin sensitivity. Obesity (Silver Spring) 2008;16:2739-2744.
25.
Catalano PM: Obesity and pregnancy the propagation of a vicious cycle? J Clin Endocrinol Metab 2003:88:3505-3506.
26.
Catalano PM, Ehrenberg HM: The short and long term implications of maternal obesity on the mother and her offspring. Br J Obstet Gynaecol 2006;113:1126-1133.
27.
Catalano PM, Tyzbir ED, Roman NM, Amini SB, Sims EA: Longitudinal changes in insulin release and insulin resistance in non-obese pregnant women. Am J Obstet Gynecol 1991;165:1667-1672.
28.
Papageorghious AT, Yu CK, Nicolaides KH: The role of uterine artery Doppler in predicting adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2004;18:383-396.
29.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
30.
American College of Endocrinology Position Statement on the insulin resistance syndrome. Endocr Pract 2003;9:237-252.
31.
Brown MA, Lindheimer MD, de Swiet M, van Assche A, Moutquin JM: The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:ix-xiv.
32.
Barton JR, Sibai BM: Prediction and prevention of recurrent preeclampsia. Obstet Gynecol 2008;112:359-372.
33.
Buchanan T, Xiang AH: Gestational diabetes mellitus. J Clin Invest 2005;115:485-491.
34.
Catalano P: Obesity, insulin resistance and pregnancy outcome. Reproduction 2010;140:365-371.
35.
Steegers E, von Dadelszen P, Duvekot J, Pijnenborg R: Pre-eclampsia. Lancet 2010;376:631-644.
36.
Dittrich R, Beckmann M, Oppelt P, Hoffmann I, Lotz L, Kuwert T, Mueller A: Thyroid hormone receptors and reproduction. J Reprod Immunol 2011;90:58-66.
37.
Ramazan Gen, Akbay E, Sezer K: Insulin resistance and cardiovascular risk factors in patients with mild and severe subclinical hypothyroidism. Endocrinologist 2010;20:128-130.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.